PKO Investment Management Joint Stock Co Makes New Investment in Insmed, Inc. $INSM

PKO Investment Management Joint Stock Co acquired a new stake in Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,967,000.

A number of other hedge funds have also modified their holdings of INSM. CIBC Private Wealth Group LLC raised its position in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC purchased a new stake in shares of Insmed in the fourth quarter valued at about $27,000. Stone House Investment Management LLC acquired a new stake in shares of Insmed during the third quarter worth about $29,000. SBI Securities Co. Ltd. grew its holdings in shares of Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC acquired a new position in Insmed in the 4th quarter valued at about $30,000.

Analyst Ratings Changes

A number of analysts have weighed in on INSM shares. UBS Group decreased their price objective on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Royal Bank Of Canada lifted their price objective on shares of Insmed from $212.00 to $216.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Roth Mkm restated a “buy” rating and set a $212.00 price objective on shares of Insmed in a research report on Friday, April 17th. Mizuho raised their target price on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 25th. Finally, Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $213.23.

Insider Activity at Insmed

In related news, COO Roger Adsett sold 88,060 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at approximately $17,584,130.30. The trade was a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the transaction, the chief executive officer owned 301,185 shares in the company, valued at $43,361,604.45. The trade was a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 179,777 shares of company stock worth $28,252,720 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Insmed Trading Down 2.3%

Shares of INSM stock opened at $133.26 on Friday. The business’s fifty day moving average price is $147.89 and its 200 day moving average price is $166.21. The firm has a market capitalization of $28.76 billion, a PE ratio of -20.79 and a beta of 0.90. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed, Inc. has a 1-year low of $63.81 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period last year, the business posted ($1.32) EPS. Insmed’s revenue was up 152.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Insmed, Inc. will post -2.51 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.